Sonoclot Analyzer, ACT Machine India, Thromboelastography, Cardiac Surgery, Liver Transplant

J Cardiothorac Vasc Anesth. 2008 Oct;22(5):670-4. Epub 2008 Mar 24. Sonoclot analysis in coronary artery surgery: a comparison between patients with unstable coronary artery disease treated with enoxaparin before surgery and patients with stable coronary artery disease not treated with enoxaparin. Pleym H, Wahba A, Bjella L, Stenseth R. Department of Cardiothoracic Anesthesia and Intensive Care, St Olav University Hospital, Trondheim, Norway. hilde.pleym@stolav.no Abstract OBJECTIVES: To investigate whether perioperative Sonoclot analyses could identify differences in hemostatic function between a group of patients with unstable coronary artery disease treated with low-molecular-weight heparin until the evening before surgery and a group of patients with stable coronary artery disease not treated with lowmolecular-weight heparin. DESIGN: Prospective and observational investigation. SETTING: A university hospital, single institution. PARTICIPANTS: Patien

Sonoclot Analyzer and Platelet Aggregometry Detect Platelet Receptor (GPIIb/IIIa) Blockade Yue Dong, M.D.; Gregory A. Nuttall, M.D.; William C. Oliver, M.D.; Mark H. Ereth, M.D. Anesthesiology, Mayo Clinic, Rochester, Minnesota, United States [Background] Abciximab blocks the major platelet surface receptor (GPIIb/IIIa), which is critical to platelet aggregation. Practical means to monitor platelet function in patients on abciximab undergoing emergency cardiac surgery is needed. [Methods] After Institutional Review Board approval and informed consent, blood samples were drawn from 20 healthy volunteers. Celite activated Sonoclot analysis and ADP activated Platelet Poor Plasma (PRP) aggregometry were completed after addition of abciximab. The Sonoclot analysis and ADP activated PRP aggregometry were used to detect platelet function. The data was analyzed by student's t test and P<0.05 is statistically significan

Monitoring fondaparinux (Low Molecular Weight Heparin Management / LMWH) with the Sonoclot Nilsson, Caroline U; Engström, Martin Abstract Fondaparinux is a new anticoagulant that interacts with antithrombin III and activated coagulation factor X resulting in an inhibition of the coagulation system. It has been successful in doses of 2.5 mg for thromboprophylaxis as well as in higher therapeutic doses of 5-7.5 mg. No optimal method for monitoring the effects of fondaparinux has been proposed. The aim of the present study was to investigate whether a viscoelastic coagulation analyzer, the Sonoclot (Sienco, Denver, Colorado, USA), could be used for in-vitro monitoring of fondaparinux. Different concentrations of fondaparinux were added in vitro to whole blood taken from eight volunteers. The blood samples mixed with the various amounts of fondaparinux were analyzed using the Sonoclot. The whole-blood activated partial thromboplastin time with the Hemochron Jr (ITC, Ediso

Celite-activated viscometer Sonoclot can measure the suppressive effect of tranexamic acid on hyperfibrinolysis in cardiac surgery Abstract Purpose. To investigate the usefulness of the celiteactivated viscometer Sonoclot for monitoring fibrinolytic status in cardiac surgery, we demonstrated the effectiveness of high doses of tranexamic acid, an antifibrinolytic agent, in reducing postoperative bleeding. Methods. Thirty-two American Society of Anesthesiologists (ASA) physical status III patients who required cardiac surgery with cardiopulmonary bypass (CPB) were studied. Anesthesia was induced by a high dose of fentanyl and midazolam with oxygen and was maintained by the intermittent administration of these agents. Patients were divided into two groups: the control group ( n = 15) and patients receiving tranexamic acid (TA; n = 17). The TA group received a high dose (50 mg/kg) of TA twice, once before and once after CPB. The percentage diminishing rate of the Sonoclot tracing